Provided by Tiger Trade Technology Pte. Ltd.

Eloxx Pharmaceuticals, Inc.

0.0001
0.0000
Volume:- -
Turnover:- -
Market Cap:330.05
PE:0.00
High:0.0001
Open:0.0001
Low:0.0001
Close:0.0001
52wk High:0.7501
52wk Low:0.0000
Shares:3.30M
Float Shares:2.72M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8163
EPS(LYR):-16.6481
ROE:-615.23%
ROA:-73.24%
PB:-0.00
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Eloxx Pharmaceuticals, Inc.
Exchange:
EXPERT
Establishment Date:
- -
Employees:
18
Office Location:
480 Arsenal Way,Suite 130,Watertown,Massachusetts,United States
Zip Code:
02472
Fax:
- -
Introduction:
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.